- Home
- UVE vs AUTL Comparison
UVE vs AUTL Comparison
Compare UVE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UVE
- AUTL
- Stock Information
- Founded
- UVE 1990
- AUTL 2014
- Country
- UVE United States
- AUTL United Kingdom
- Employees
- UVE N/A
- AUTL N/A
- Industry
- UVE Property-Casualty Insurers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UVE Finance
- AUTL Health Care
- Exchange
- UVE Nasdaq
- AUTL Nasdaq
- Market Cap
- UVE 666.1M
- AUTL 625.4M
- IPO Year
- UVE 1992
- AUTL 2018
- Fundamental
- Price
- UVE $24.59
- AUTL $1.75
- Analyst Decision
- UVE
- AUTL Strong Buy
- Analyst Count
- UVE 0
- AUTL 5
- Target Price
- UVE N/A
- AUTL $9.12
- AVG Volume (30 Days)
- UVE 203.1K
- AUTL 2.7M
- Earning Date
- UVE 07-24-2025
- AUTL 08-12-2025
- Dividend Yield
- UVE 3.13%
- AUTL N/A
- EPS Growth
- UVE N/A
- AUTL N/A
- EPS
- UVE 2.28
- AUTL N/A
- Revenue
- UVE $1,567,371,000.00
- AUTL $29,934,000.00
- Revenue This Year
- UVE $1.87
- AUTL $472.28
- Revenue Next Year
- UVE N/A
- AUTL $114.92
- P/E Ratio
- UVE $10.80
- AUTL N/A
- Revenue Growth
- UVE 5.64
- AUTL 185.17
- 52 Week Low
- UVE $16.50
- AUTL $1.11
- 52 Week High
- UVE $28.49
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- UVE 53.88
- AUTL 32.10
- Support Level
- UVE $23.32
- AUTL $1.70
- Resistance Level
- UVE $24.71
- AUTL $1.89
- Average True Range (ATR)
- UVE 0.48
- AUTL 0.15
- MACD
- UVE 0.18
- AUTL -0.06
- Stochastic Oscillator
- UVE 80.75
- AUTL 11.49
About UVE UNIVERSAL INSURANCE HOLDINGS INC
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.